LUM001 (Maralixibat) + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alagille Syndrome
Conditions
Alagille Syndrome
Trial Timeline
Oct 28, 2014 → May 28, 2020
NCT ID
NCT02160782About LUM001 (Maralixibat) + Placebo
LUM001 (Maralixibat) + Placebo is a phase 2 stage product being developed by Mirum Pharmaceuticals for Alagille Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02160782. Target conditions include Alagille Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02160782 | Phase 2 | Completed |
Competing Products
9 competing products in Alagille Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Odevixibat + Placebo | Ipsen | Phase 3 | 74 |
| Odevixibat | Ipsen | Phase 3 | 74 |
| LUM001 (Maralixibat) | Mirum Pharmaceuticals | Phase 2 | 49 |
| maralixibat | Mirum Pharmaceuticals | Pre-clinical | 20 |
| Livmarli + Livmarli | Mirum Pharmaceuticals | Pre-clinical | 20 |
| LUM001 (Maralixibat) | Mirum Pharmaceuticals | Phase 2 | 49 |
| Livmarli Oral Product | Mirum Pharmaceuticals | Approved | 82 |
| LUM001 + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |
| LUM001 + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |